Mulberry Biotherapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Mulberry Biotherapeutics General Information

Description

Operator of a biotechnology company intended to develop treatments for cancer disease. The company is focused on delivering transformative improvements in the health and quality of life to individuals affected by the rare genetic disorder neurofibromatosis Type 2, enabling patients to get treatment for the disease.

Contact Information

Website
www.mulberrybio.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 40 Walnut Street
  • Suite 301
  • Wellesley, MA 02481
  • United States
Primary Industry
Drug Discovery
Parent Company
Neopharm Group
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 40 Walnut Street
  • Suite 301
  • Wellesley, MA 02481
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mulberry Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Oct-2025 Completed Generating Revenue
2. Early Stage VC (Series A) 20-Apr-2021 Completed Generating Revenue
1. Grant 01-Jan-2020 $698K Completed Generating Revenue
To view Mulberry Biotherapeutics’s complete valuation and funding history, request access »

Mulberry Biotherapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Mulberry Biotherapeutics’s complete cap table history, request access »

Mulberry Biotherapeutics Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
CH Innovations Not-For-Profit Venture Capital Minority
Community Impact Ventures Impact Investing Minority
National Institutes of Health Government
U.S. Department of Health and Human Services Government
To view Mulberry Biotherapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Mulberry Biotherapeutics FAQs

  • When was Mulberry Biotherapeutics founded?

    Mulberry Biotherapeutics was founded in 2020.

  • Where is Mulberry Biotherapeutics headquartered?

    Mulberry Biotherapeutics is headquartered in Wellesley, MA.

  • What industry is Mulberry Biotherapeutics in?

    Mulberry Biotherapeutics’s primary industry is Drug Discovery.

  • Is Mulberry Biotherapeutics a private or public company?

    Mulberry Biotherapeutics is a Private company.

  • What is Mulberry Biotherapeutics’s current revenue?

    The current revenue for Mulberry Biotherapeutics is .

  • How much funding has Mulberry Biotherapeutics raised over time?

    Mulberry Biotherapeutics has raised $2.8M.

  • Who are Mulberry Biotherapeutics’s investors?

    CH Innovations, Community Impact Ventures, National Institutes of Health, and U.S. Department of Health and Human Services have invested in Mulberry Biotherapeutics.

  • When was Mulberry Biotherapeutics acquired?

    Mulberry Biotherapeutics was acquired on 01-Oct-2025.

  • Who acquired Mulberry Biotherapeutics?

    Mulberry Biotherapeutics was acquired by Neopharm Group.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process